JPWO2020096988A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020096988A5 JPWO2020096988A5 JP2021524021A JP2021524021A JPWO2020096988A5 JP WO2020096988 A5 JPWO2020096988 A5 JP WO2020096988A5 JP 2021524021 A JP2021524021 A JP 2021524021A JP 2021524021 A JP2021524021 A JP 2021524021A JP WO2020096988 A5 JPWO2020096988 A5 JP WO2020096988A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- til
- til population
- tils
- expansion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 claims 100
- 230000001225 therapeutic Effects 0.000 claims 25
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims 23
- 210000004027 cells Anatomy 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 239000006143 cell culture media Substances 0.000 claims 11
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims 10
- 108010002350 Interleukin-2 Proteins 0.000 claims 8
- 230000014828 interferon-gamma production Effects 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000003306 harvesting Methods 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 6
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 210000003162 effector T lymphocyte Anatomy 0.000 claims 4
- 239000010410 layer Substances 0.000 claims 4
- 210000003071 memory T lymphocyte Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 238000005138 cryopreservation Methods 0.000 claims 3
- 239000012595 freezing medium Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 102100019461 CD28 Human genes 0.000 claims 2
- 101700033362 CD28 Proteins 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000005017 Glioblastoma Diseases 0.000 claims 2
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 108090000393 Muromonab-CD3 Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002496 gastric Effects 0.000 claims 2
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001502 supplementation Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 230000000735 allogeneic Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000002344 surface layer Substances 0.000 claims 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862755954P | 2018-11-05 | 2018-11-05 | |
US62/755,954 | 2018-11-05 | ||
US201962903585P | 2019-09-20 | 2019-09-20 | |
US62/903,585 | 2019-09-20 | ||
PCT/US2019/059718 WO2020096988A2 (en) | 2018-11-05 | 2019-11-04 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022506586A JP2022506586A (ja) | 2022-01-17 |
JPWO2020096988A5 true JPWO2020096988A5 (de) | 2022-11-14 |
Family
ID=69165500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021524021A Pending JP2022506586A (ja) | 2018-11-05 | 2019-11-04 | 腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用 |
Country Status (19)
Country | Link |
---|---|
US (3) | US20220090018A1 (de) |
EP (1) | EP3877513A2 (de) |
JP (1) | JP2022506586A (de) |
KR (1) | KR20210091213A (de) |
CN (1) | CN113272421A (de) |
AU (1) | AU2019374761A1 (de) |
BR (1) | BR112021008573A2 (de) |
CA (1) | CA3118624A1 (de) |
CL (1) | CL2021001178A1 (de) |
CO (1) | CO2021007362A2 (de) |
CR (1) | CR20210295A (de) |
IL (1) | IL282919A (de) |
JO (1) | JOP20210094A1 (de) |
MX (1) | MX2021005216A (de) |
PE (1) | PE20211292A1 (de) |
PH (1) | PH12021551033A1 (de) |
SG (1) | SG11202104615VA (de) |
TW (1) | TW202039830A (de) |
WO (1) | WO2020096988A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
WO2019210131A1 (en) * | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2020232029A1 (en) * | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ (ユーケイ) リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
TW202237822A (zh) * | 2020-11-19 | 2022-10-01 | 大陸商蘇州沙礫生物科技有限公司 | 腫瘤浸潤淋巴細胞的培養方法及其用途 |
CA3201818A1 (en) | 2020-12-11 | 2022-06-16 | Maria Fardis | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
EP4262827A1 (de) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Behandlung von krebs mit tumorinfiltrierenden lymphozyten |
WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
TW202242085A (zh) | 2020-12-31 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 供自動生產腫瘤浸潤淋巴球的裝置和方法 |
CN114686430A (zh) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | 一种制备til的方法 |
TW202241508A (zh) * | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
EP4288140A1 (de) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvante therapie für krebs |
TW202300014A (zh) | 2021-03-05 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 腫瘤儲存及細胞培養組成物 |
CA3212439A1 (en) | 2021-03-19 | 2022-09-22 | Michelle SIMPSON-ABELSON | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
IL306072A (en) | 2021-03-25 | 2023-11-01 | Iovance Biotherapeutics Inc | Methods and preparations for T-cell coculture potency assays and use with cellular therapy products |
CA3219148A1 (en) | 2021-05-17 | 2022-11-24 | Frederick G. Vogt | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
TW202328439A (zh) | 2021-09-09 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 使用pd-1 talen基因減弱生成til產物之方法 |
EP4404969A1 (de) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansionsverfahren und mittel für tumorinfiltrierende lymphozyten |
AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023138598A1 (zh) * | 2022-01-19 | 2023-07-27 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞在疾病治疗中的用途 |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
CN117683121B (zh) * | 2024-01-30 | 2024-04-16 | 北京百普赛斯生物科技股份有限公司 | 抗水痘-带状疱疹病毒抗体及其应用 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2318394A (en) | 1941-08-22 | 1943-05-04 | Raymond T Moloney | Game apparatus |
US2705482A (en) | 1951-04-19 | 1955-04-05 | Glenn T Randol | Mechanical self-adjusting valve lifter |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5128257A (en) | 1987-08-31 | 1992-07-07 | Baer Bradford W | Electroporation apparatus and process |
WO1989006555A1 (en) | 1988-01-21 | 1989-07-27 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
ZA902710B (en) | 1989-05-22 | 1991-12-24 | Univ Georgia Res Found | Enzyme luminescence assay |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
CA2019758C (en) | 1990-06-25 | 2001-09-04 | Kevin L. Firth | Improved electroporation device and method |
US5137817A (en) | 1990-10-05 | 1992-08-11 | Amoco Corporation | Apparatus and method for electroporation |
US5173158A (en) | 1991-07-22 | 1992-12-22 | Schmukler Robert E | Apparatus and methods for electroporation and electrofusion |
US5304120A (en) | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5318514A (en) | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
GB9317380D0 (en) | 1993-08-20 | 1993-10-06 | Therexsys Ltd | Transfection process |
US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
CA2193954A1 (en) | 1994-06-27 | 1996-01-04 | Vu L. Truong | Targeted gene delivery system |
US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
ATE226641T1 (de) | 1995-04-08 | 2002-11-15 | Lg Chemical Ltd | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
PL188749B1 (pl) | 1996-10-11 | 2005-04-29 | Bristol Myers Squibb Co | Zastosowanie przeciwciała anty-4-1BB i kompozycjaleku |
CA2277278A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
DK0973928T3 (da) | 1997-03-11 | 2010-08-09 | Univ Minnesota | DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6475994B2 (en) | 1998-01-07 | 2002-11-05 | Donald A. Tomalia | Method and articles for transfection of genetic material |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
AU746454B2 (en) | 1998-03-02 | 2002-05-02 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
EP1353701B1 (de) | 2000-10-31 | 2011-12-21 | PR Pharmaceuticals, Inc. | Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen |
US7550140B2 (en) | 2002-06-13 | 2009-06-23 | Crucell Holland B.V. | Antibody to the human OX40 receptor |
US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
EP2336293B1 (de) | 2003-10-08 | 2016-02-10 | Wilson Wolf Manufacturing Corporation | Zellkulturverfahren und Vorrichtungen mit Nutzung gasdurchlässiger Materialien |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
CA2585776A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
EP1877090B1 (de) | 2005-05-06 | 2014-01-15 | Providence Health System | Trimeres ox40-immunglobulin-fusionsprotein und verwendungsverfahren |
TWI466269B (zh) | 2006-07-14 | 2014-12-21 | Semiconductor Energy Lab | 非揮發性記憶體 |
EP1894940A1 (de) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF Superfamilie Fusionsproteine |
RU2009135824A (ru) | 2007-02-27 | 2011-04-10 | Дженентек, Инк. (Us) | Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний |
CA2692802C (en) | 2007-07-10 | 2017-05-30 | Oliver Hill | Tnf superfamily collectin fusion proteins |
EP2205740A2 (de) | 2007-10-02 | 2010-07-14 | Rxi Pharmaceuticals Corp. | Dreiteilige rnai-konstrukte |
BRPI0820875B1 (pt) | 2007-12-14 | 2021-10-19 | Bristol-Myers Squibb Company | Molécula de ligação isolada, anticorpo monoclonal humano, composição, molécula de ácido nucleico, vetor e célula hospedeira |
JP5697993B2 (ja) | 2008-02-11 | 2015-04-08 | アールエックスアイ ファーマシューティカルズ コーポレーション | 修飾RNAiポリヌクレオチドおよびその使用 |
US8592557B2 (en) | 2008-06-17 | 2013-11-26 | Apogenix Gmbh | Multimeric TNF receptor fusion proteins and nucleic acids encoding same |
CA2731388C (en) | 2008-07-21 | 2018-05-01 | Apogenix Gmbh | Tnfsf single chain molecules |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
WO2010078966A1 (en) | 2009-01-09 | 2010-07-15 | Apogenix Gmbh | Fusion proteins forming trimers |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
CA2783550A1 (en) | 2009-12-08 | 2011-06-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
EP2550000A4 (de) | 2010-03-24 | 2014-03-26 | Advirna Inc | Selbstfreisetzende rnai-verbindungen von reduzierter grösse |
CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
KR102453078B1 (ko) | 2010-03-24 | 2022-10-11 | 피오 파마슈티칼스 코프. | 진피 및 섬유증성 적응증에서의 rna 간섭 |
AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
JP2013534417A (ja) | 2010-06-14 | 2013-09-05 | アイオワ ステート ユニバーシティ リサーチ ファウンデーション,インコーポレーティッド | Talエフェクターとfokiの融合タンパク質のヌクレアーゼ活性 |
NZ629913A (en) | 2010-08-23 | 2016-01-29 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
HUE041958T2 (hu) | 2010-09-09 | 2019-06-28 | Pfizer | 4-IBB-t kötõ molekulák |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
KR102349549B1 (ko) | 2010-11-12 | 2022-01-11 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
JP5996630B2 (ja) | 2011-04-05 | 2016-09-21 | セレクティスCellectis | コンパクトtale−ヌクレアーゼを作製する方法及びその使用 |
US20140234320A1 (en) | 2011-06-20 | 2014-08-21 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
CN103946238B (zh) | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
PL2768942T3 (pl) | 2011-10-17 | 2020-05-18 | Massachusetts Institute Of Technology | Dostarczanie dokomórkowe |
JP6386447B2 (ja) | 2012-05-18 | 2018-09-05 | ウィルソン ウォルフ マニュファクチャリング コーポレイションWilson Wolf Manufacturing Corporation | 養子細胞療法のための改良された細胞培養法 |
HUE064187T2 (hu) | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
US10815500B2 (en) | 2012-06-05 | 2020-10-27 | Cellectis | Transcription activator-like effector (TALE) fusion protein |
AU2013274416B2 (en) | 2012-06-11 | 2019-07-04 | Wilson Wolf Manufacturing, LLC | Improved methods of cell culture for adoptive cell therapy |
KR20150105635A (ko) | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
CN113528577A (zh) | 2012-12-12 | 2021-10-22 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
AU2013359212B2 (en) | 2012-12-12 | 2017-01-19 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
PL2931898T3 (pl) | 2012-12-12 | 2016-09-30 | Le Cong | Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi |
JP6416131B2 (ja) | 2013-03-01 | 2018-10-31 | アメリカ合衆国 | 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法 |
LT2976361T (lt) | 2013-03-18 | 2018-10-25 | Biocerox Products B.V. | Humanizuoti antikūnai prieš receptorių cd134 (ox40) ir jų naudojimas |
US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
EP3004320A4 (de) | 2013-06-24 | 2017-05-17 | Wilson Wolf Manufacturing Corporation | Vorrichtung mit geschlossenem system und verfahren für gasdurchlässiges zellkulturverfahren |
RU2744194C2 (ru) | 2013-12-02 | 2021-03-03 | Фио Фармасьютикалс Корп | Иммунотерапия рака |
US20150190506A1 (en) | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
WO2015119923A1 (en) | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer |
CN106574244B (zh) | 2014-06-11 | 2022-01-07 | 保利比奥斯博特有限责任公司 | 用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗 |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
JP6925984B2 (ja) | 2015-07-09 | 2021-08-25 | マサチューセッツ インスティテュート オブ テクノロジー | 無核細胞への物質の送達 |
CA3002744A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
EP3402890A1 (de) | 2016-01-12 | 2018-11-21 | SQZ Biotechnologies Company | Intrazelluläre verabreichung von komplexen |
MX2019004707A (es) * | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
TWI788307B (zh) * | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
-
2019
- 2019-11-04 SG SG11202104615VA patent/SG11202104615VA/en unknown
- 2019-11-04 BR BR112021008573-4A patent/BR112021008573A2/pt unknown
- 2019-11-04 TW TW108139990A patent/TW202039830A/zh unknown
- 2019-11-04 US US17/290,708 patent/US20220090018A1/en active Pending
- 2019-11-04 CN CN201980087860.4A patent/CN113272421A/zh active Pending
- 2019-11-04 WO PCT/US2019/059718 patent/WO2020096988A2/en unknown
- 2019-11-04 EP EP19836648.6A patent/EP3877513A2/de active Pending
- 2019-11-04 PE PE2021000667A patent/PE20211292A1/es unknown
- 2019-11-04 AU AU2019374761A patent/AU2019374761A1/en active Pending
- 2019-11-04 CA CA3118624A patent/CA3118624A1/en active Pending
- 2019-11-04 JO JOP/2021/0094A patent/JOP20210094A1/ar unknown
- 2019-11-04 CR CR20210295A patent/CR20210295A/es unknown
- 2019-11-04 KR KR1020217017220A patent/KR20210091213A/ko unknown
- 2019-11-04 JP JP2021524021A patent/JP2022506586A/ja active Pending
- 2019-11-04 MX MX2021005216A patent/MX2021005216A/es unknown
-
2021
- 2021-05-04 IL IL282919A patent/IL282919A/en unknown
- 2021-05-05 PH PH12021551033A patent/PH12021551033A1/en unknown
- 2021-05-05 CL CL2021001178A patent/CL2021001178A1/es unknown
- 2021-06-04 CO CONC2021/0007362A patent/CO2021007362A2/es unknown
-
2024
- 2024-01-11 US US18/410,900 patent/US20240240146A1/en active Pending
- 2024-01-12 US US18/411,991 patent/US20240228963A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2020096988A5 (de) | ||
JP2021503281A5 (de) | ||
JP2020515257A5 (de) | ||
US20230000919A1 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
Eberlein et al. | Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. | |
US5766920A (en) | Ex vivo activation of immune cells | |
WO2020159360A1 (en) | Pharmaceutical composition for use in the treatment of pancreatic cancer | |
JP2001520509A (ja) | 自己免疫細胞療法:細胞組成物、方法およびヒト疾患の治療への応用 | |
JP7105188B2 (ja) | 幹細胞移植方法 | |
FI3843759T3 (fi) | Tuumoriin filtroituvien lymfosyyttien käyttö anti-PD-1-vasta-aineelle vastustuskykyisten NSCLC-potilaiden hoitoon | |
FR2836483A1 (fr) | Procedes de production de lymphocytes gamma delta t | |
KR20210120067A (ko) | 췌장암 치료용 약학 조성물 | |
JP2010220479A (ja) | Nk細胞の培養方法及びnk細胞の利用 | |
JPWO2020131547A5 (de) | ||
JP7502813B2 (ja) | 汎用型の臨床における異体dnt細胞の複数回再注入用の効率的体外増幅方法 | |
Stroncek et al. | Developments in clinical cell therapy | |
EP2606125B1 (de) | Zellen zur expression von th1-merkmalen und zytolytischen eigenschaften | |
CN110029088A (zh) | 肿瘤细胞凋亡小体及其制备方法和应用 | |
CN103861107B (zh) | 一种药物组合物及其用途 | |
CN106795493A (zh) | 使用双膦酸盐、抗cd3抗体和il‑2扩增t细胞群体 | |
JPWO2020096989A5 (de) | ||
US20230295566A1 (en) | Method for producing tumor-infiltrating t-lymphocytes (til) and their use as cellular therapeutics for the treatment of human tumors | |
EP0804550A1 (de) | Die ex vivo aktivierung von immunzellen | |
EP0825255A1 (de) | Verfahren zur Herstellung aktivierter Killer-Monozyten | |
JPWO2021226061A5 (de) |